Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Replimune (REPL) Cash & Equivalents (2018 - 2025)

Replimune has reported Cash & Equivalents over the past 8 years, most recently at $123.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $123.0 million for Q4 2025, down 28.62% from a year ago — trailing twelve months through Dec 2025 was $123.0 million (down 28.62% YoY), and the annual figure for FY2025 was $111.1 million, up 49.24%.
  • Cash & Equivalents reached $123.0 million in Q4 2025 per REPL's latest filing, up from $102.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $206.7 million in Q4 2022 and bottomed at $74.5 million in Q1 2024.
  • Median Cash & Equivalents over the past 5 years was $112.9 million (2022), compared with a mean of $124.9 million.
  • Peak annual rise in Cash & Equivalents hit 397.16% in 2021, while the deepest fall reached 59.23% in 2021.
  • Over 5 years, Cash & Equivalents stood at $132.3 million in 2021, then skyrocketed by 56.24% to $206.7 million in 2022, then plummeted by 52.74% to $97.7 million in 2023, then surged by 76.35% to $172.2 million in 2024, then decreased by 28.62% to $123.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for REPL at $123.0 million in Q4 2025, $102.3 million in Q3 2025, and $97.4 million in Q2 2025.